Overcoming radioresistance with the hypoxia-activated prodrug CP-506: A pre-clinical study of local tumour control probability

•CP-506 is a novel hypoxia-activated prodrug with broad anti-tumour activity.•CP-506 significantly improved local tumour control when combined with single dose radiation in contrast to fractionated radiotherapy.•The magnitude of the therapeutic effect depends on the tumour model, highlighting the ne...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Radiotherapy and oncology 2023-09, Vol.186, p.109738-109738, Article 109738
Hauptverfasser:	Yaromina, Ala, Koi, Lydia, Schuitmaker, Lesley, van der Wiel, Alexander Marie-Madeleine Adrianus, Dubois, Ludwig Jerome, Krause, Mechthild, Lambin, Philippe
Format:	Artikel
Sprache:	eng
Schlagworte:	Hypoxia Hypoxia-activated prodrug CP-506 Local control Radiotherapy Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!